Literature DB >> 2552075

Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.

H N Bhargava1, A Gulati, P Ramarao.   

Abstract

The effects of chronic administration of U-50,488H (trans-3,4-dichloro-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeacetamide ), a selective kappa opioid agonist, on the development of tolerance to its analgesic and hypothermic effects and on mu, delta and kappa opioid receptors in brain regions and spinal cord of male Sprague-Dawley rats were determined. Rats were injected i.p. twice daily with 25 mg/kg of U-50,488H for 4 days. The development of tolerance to the analgesic and hypothermic effects of U-50,488H was almost complete after 4 days of treatment. [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), [3H]Tyr-D-Ser-Gly-Phe-Leu-Thr (DSTLE) and [3H]ethylketocyclazocine (EK) were used as ligands for mu, delta and kappa opioid receptors, respectively. The binding of [3H]DAMGO to membranes prepared from various brain regions (pons + medulla, midbrain, hypothalamus, corpus striatum and cortex) and spinal cord was unaffected by chronic administration of U-50,488H. The binding of [3H]DSTLE in U-50,488H-treated rats was decreased in spinal cord and increased in corpus striatum. The binding of [3H]EK to membranes prepared from pons + medulla, midbrain, cortex and spinal cord was decreased whereas it was increased in the corpus striatum. The changes in the binding of [3H]DSTLE and [3H]EK after chronic treatment with U-50,488H were due to changes in the maximum binding values and not in the Kd values. The results indicate that, in the rat, chronic administration of U-50,488H results in the development of tolerance to its analgesic and hypothermic effects and down-regulation of kappa and delta opioid receptors in the spinal cord and an up-regulation in the corpus striatum.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552075

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  kappa-Opioid tolerance and dependence in cultures of dopaminergic midbrain neurons.

Authors:  F C Dalman; K L O'Malley
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

2.  Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females.

Authors:  Cindee F Robles; Marissa Z McMackin; Katharine L Campi; Ian E Doig; Elizabeth Y Takahashi; Michael C Pride; Brian C Trainor
Journal:  Behav Brain Res       Date:  2014-01-18       Impact factor: 3.332

Review 3.  Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Authors:  Michael R Bruchas; Charles Chavkin
Journal:  Psychopharmacology (Berl)       Date:  2010-04-17       Impact factor: 4.530

4.  Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase mRNA expression, phosphorylation, and enzyme activity in the nucleus of the solitary tract during morphine withdrawal.

Authors:  Cristina Núñez; Anna Földes; Domingo Pérez-Flores; J Carlos García-Borrón; M Luisa Laorden; Krisztina J Kovács; M Victoria Milanés
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

5.  Cross-tolerance of associative and nonassociative morphine tolerance in the rat with mu- and kappa-specific opioids.

Authors:  B L Carter; S T Tiffany
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

6.  Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.

Authors:  N J Talley; R S Choung; M Camilleri; R A Dierkhising; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  2008-03-07       Impact factor: 8.171

7.  Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.

Authors:  Yu-Jun Wang; Yi-Min Tao; Fu-Ying Li; Yu-Hua Wang; Xue-Jun Xu; Jie Chen; Ying-Lin Cao; Zhi-Qiang Chi; John L Neumeyer; Ao Zhang; Jing-Gen Liu
Journal:  J Pharmacol Exp Ther       Date:  2009-01-09       Impact factor: 4.030

8.  Beneficial effects of co-treatment with dextromethorphan on prenatally methadone-exposed offspring.

Authors:  Yao-Chang Chiang; Li-Ci Ye; Kuei-Ying Hsu; Chien-Wei Liao; Tsai-Wei Hung; Wan-Jou Lo; Ing-Kang Ho; Pao-Luh Tao
Journal:  J Biomed Sci       Date:  2015-03-20       Impact factor: 8.410

9.  Polymethoxyflavones from Nicotiana plumbaginifolia (Solanaceae) Exert Antinociceptive and Neuropharmacological Effects in Mice.

Authors:  Md Shafiullah Shajib; Ridwan B Rashid; Long C Ming; Shanta Islam; Md Moklesur R Sarker; Lutfun Nahar; Satyajit D Sarker; Bidyut K Datta; Mohammad A Rashid
Journal:  Front Pharmacol       Date:  2018-02-20       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.